GlaxoSmithKline investigator John Kraus reviewed the long-awaited mid-stage results for its Duchenne muscular dystrophy drug drisapersen this afternoon, revealing that boys taking the experimental ...
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the ...
Objective: To assess the association of weekly walking distance to body weight and waist circumference in elderly (age ⩾75 years), senior (55⩽ age <75 years), middle-aged (35⩽ age <55 years), and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback